drugset / Trial / NCT01657799

Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer

NCT01657799

Phase 2 Completed 307 enrolled AbbVie
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy and safety of veliparib and whole brain radiation therapy in adults with brain metastases from non-small cell lung cancer (NSCLC).

Timeline

Start
2012-10-19
Primary completion
2015-01-22
Completion
2015-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Veliparib Small molecule 50 mg Oral
Subject Veliparib Small molecule 200 mg Oral